Global Ophthalmics Partnering 2014 to 2020 provides the full collection of Ophthalmics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
Trends in Ophthalmics partnering deals Financial deal terms for headline, upfront and royalty by stage of development Ophthalmics partnering agreement structure Ophthalmics partnering contract documents Top Ophthalmics deals by value Most active Ophthalmics dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Ophthalmics deals.
The report presents financial deal terms values for Ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Ophthalmics dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Ophthalmics dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Ophthalmics deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Ophthalmics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Ophthalmics deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Ophthalmics partnering deals by specific Ophthalmics target announced since 2014. The chapter is organized by specific Ophthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Ophthalmics partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Ophthalmics partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Ophthalmics technologies and products.
Report scope Global Ophthalmics Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Ophthalmics trends and structure of deals entered into by leading companies worldwide.
Global Ophthalmics Partnering 2014 to 2020 includes: Trends in Ophthalmics dealmaking in the biopharma industry since 2014 Analysis of Ophthalmics deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Ophthalmics deal contract documents Comprehensive access to over 440 Ophthalmics deal records The leading Ophthalmics deals by value since 2014 Most active Ophthalmics dealmakers since 2014
The report includes deals for the following indications: Age-related macular degeneration, Blindness, Cataracts, Conjunctivitis, Diabetic macular edema, Dry eye, Glaucoma, Ocular hypertension, Retinal detachment Retinopathy, Diabetic retinopathy, Uveitis, plus other ophthalmic indications.
In Global Ophthalmics Partnering 2014 to 2020, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Ophthalmics Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 440 ophthalmics deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are the sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Contact Lenses Market Report The contact lenses market by revenue is expected to grow at a CAGR of over 5% during the period 2019–2025. The global contact lenses market has observed a decline of around $1,409.62 million due to the outbreak...
The global contact lenses market size is projected to reach USD 10.2 billion by 2025 from USD 7.4 billion in 2020, at a CAGR of 6.7%. Market growth is driven mainly by the growing prevalence of myopia, increasing preference for contact lenses over prescription eyeglasses, and the ever-increasing geriatric population worldwide. The untapped...
Saudi Arabia E-Commerce Eyewear Market is projected to grow at a CAGR of 5.56% during the forecast period (2020- 2025). - The country’s harsh and humid climate, along with a growing share of smartphones users, has let the eye wear market to gain traction in the region. That said, most of the demand is met by tourists, often including...
200 pages •
By The Business Research Company
• Sep 2020
Major players in the diagnostic and monitoring ophthalmic devices and equipment market are Carl Zeiss Meditec, Alcon, Bausch + Lomb, Haag-Streit and Topcon Corporation. The global diagnostic and monitoring ophthalmic devices and equipment market is expected to decline from $1.4 billion in 2019 to $1.1 billion in 2020 at a compound annual...
Contact Lens Solution Market Research Report by Type (Clean-Type, Disinfectant, Flush and Saving, Hydrogen peroxide-based, and Multi-purpose), by Volume Channel (120mL, 360mL, and 480mL), by Material, by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Contact Lens Solution Market...
200 pages •
By The Business Research Company
• Sep 2020
Major players in the vision care devices and equipment market are Essilor, Johnson & Johnson, ZEISS, The Cooper Companies and Novartis. The global vision care devices and equipment market is expected to decline from $27.8 billion in 2019 to $21.8 billion in 2020 at a compound annual growth rate (CAGR) of -21.5%. The decline is mainly...
Coronary Stents - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Coronary Stents - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Coronary Stents pipeline products with comparative analysis of the products at various stages...
268 pages •
By The Business Research Company
• Oct 2020
Analytical Laboratory Instruments Global Market Opportunities And Strategies To 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global analytical laboratory instruments market. Description: Where is the largest and fastest growing market for the...
Cardiopulmonary Bypass Equipment - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Cardiopulmonary Bypass Equipment - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Cardiopulmonary Bypass Equipment pipeline products with comparative...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.